Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 12, 2018

View Archived Issues

RNAi-mediated beta-catenin inhibition increases response rates to cancer immunotherapy in mice

Noncoding DNA affects heart risk via noncoding RNA

Considering neighborhood improves neoantigen prediction

Loxo Oncology initiates phase I/II trial of LOXO-305 in CLL/SLL and NHL

Gritstone Oncology begins phase I/II study of personalized neoantigen cancer vaccine in solid tumors

Aravive initiates phase I/II study of AVB-S6-500 in platinum-resistant recurrent ovarian cancer

Novel 7-gene expression signature accurately predicts breast cancer outcome

Enrollment opens in two studies of Xhance

Interim phase II results presented for BP-1001 in AML

High synaptojanin 2 expression predicts poor prognosis in ER-positive breast cancer

Long noncoding RNA LINC02273 regulates oncogenic gene expression and breast cancer metastasis

ME1 is a prognostic marker and potential therapeutic target in breast cancer

High periostin levels predict shorter survival in primary, nonmetastatic breast cancer

Liver injury regeneration strategy bypasses fibrosis

Alligator Bioscience initiates first-in-human study of ATOR-1015

Aplidin approved in Australia for the treatment of multiple myeloma

Positive second cohort data from phase I study of Oraxol plus ramucirumab in gastric cancer

MyoKardia reports phase Ib data for MYK-491

Lilly identifies new calcitonin gene-related peptide receptor antagonists

New adrenomedullin-2 antagonists synthesized at the University of Sheffield

Novan reports fourth cohort data from phase II trial of SB-206 for molluscum contagiosum

FDA approves Tolsura for systemic fungal infections

Noxopharm advances DARRT-1 study of Veyonda in late-stage prostate cancer

Arcus Biosciences patents adenosine receptor A2A and/or A2B antagonists

RIP-1 inhibitors discovered at Denali Therapeutics

University of Michigan divulges lysine-specific histone demethylase 1A inhibitors

Vect-Horus enters research collaboration agreement with Janssen

Aeglea announces phase III plans for pegzilarginase in arginase 1 deficiency

FDA accepts IND for Sermonix's phase II trial of oral lasofoxifene in breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...